Background: CpG island methylator phenotype (CIMP) has been identified as a distinct molecular subtype of gastric cancer, yet associations with survival are conflicting. A meta-analysis was performed to estimate the prognostic significance of CIMP.
Introduction
Gastric cancer is the second commonest cause of cancer-related death worldwide, accounting for around 740 000 deaths annually 1 . Surgery remains the only treatment with curative potential, but some 40 per cent of patients develop recurrence and die from the disease. Response rates to chemotherapy are poor, and prescribing adjuvant chemotherapy to all patients has no evidence base and is not recommended. Hence, one of the prime challenges is to identify biomarkers that may improve prognostic modelling, independent of the current AJCC TNM staging system, and which may promote new therapeutic targets.
The molecular mechanism underlying gastric cancer carcinogenesis remains unclear; however, genomic and epigenetic changes are important causes of activation of oncogenes and silencing of tumour suppression genes (TSGs). Epigenetic silencing through hypermethylation of CpG islands of the gene's promoter region plays an important role in silencing tumour-related genes 2 . There is conflicting evidence regarding the relationship between CpG island methylator phenotype (CIMP) and survival 3, 4 . The relatively small sample sizes in studies reporting an association between CIMP positivity and survival make it difficult to interpret the true prognostic influence of this biomarker. A possible solution is to undertake a meta-analysis of published data. Unfortunately, the meta-analysis performed by Zong and Seto 5 contained only two studies reporting the prognostic value of CIMP. Therefore, the aim of the present study was to perform a systematic review and meta-analysis of the prognostic value of CIMP status in gastric cancer using overall survival as the time-to-event endpoint. Studies providing sufficient data for inclusion in meta-analysis n = 10
Full-text articles excluded n = 4 No extractable data n = 4
Screened by title and abstract n = 110
Full-text articles assessed for eligibility n = 14 
Methods

Search protocol
Original studies were searched for those that documented patients with surgically resected primary gastric adenocarcinoma, whose specimens were assessed for the presence of CIMP. The outcome measure chosen was 5-year overall survival. Embase, MEDLINE, PubMed, PubMed Central and Cochrane databases were searched for articles published up to March 2017 using the following Boolean search term: CpG island methylator phenotype AND (cancer OR carcinoma OR adenocarcinoma OR tumor OR tumour) AND (gastric OR stomach). All search results were combined in a reference manager database and duplicates removed. A grey search of reference lists of included studies was also undertaken.
Study selection
All types of original scientific report were considered. Reviews and book chapters were excluded, as were texts written in languages other than English, and reports including survival analysis or patients who did not undergo surgery with curative intent. Only studies related to the association between CIMP and survival in patients undergoing potentially curative resection for gastric cancer were included.
Data extraction
Two independent reviewers applied the inclusion criteria to study abstracts and selected full papers for data analysis. Data from full-text papers were extracted by a single reviewer, with 50 per cent undergoing independent review. Discrepancies were verified by consensus. If multiple publications reported results in the same population, the most comprehensive data were chosen. For each study, baseline data (author, institution, country, study interval, total number of patients, sex, TNM stage, CIMP definition and methodology) were extracted. The number of patients exhibiting CIMP, and 5-year all-cause death rates were obtained where available. Outcomes were described as odds ratios (ORs) with 95 per cent confidence intervals. Where these were not reported, the methods described by Rogers et al. 6 and Parmar and colleagues 7 were used to extract data from Kaplan-Meier curves, or percentage *Values are mean, except †median. ‡Tumours were staged according to the relevant AJCC TNM staging system at the time of surgery 18, 19 . §Patients did not receive neoadjuvant chemotherapy; for other studies it is not known whether neoadjuvant +/-adjuvant chemotherapy was administered. n.r., Not reported.
survival. Authors were contacted if the data were not presented in a usable form.
Definition of CpG island methylator phenotype
No consensus on the most accurate method of assessing CIMP exists; there has been variation in the cut-off for gene promoter methylation, and the number and type of genes studied. For this reason, the term defined in each included paper is presented in the results. For the analysis, CIMP was determined to be either present (positive) or absent (negative). Where CIMP was graded into groups (high (CIMP-H), low (CIMP-L) or none (CIMP-N)), the results for the CIMP-L/CIMP-N groups were combined (CIMP-negative) and compared with those of the CIMP-H (CIMP-positive) group.
Quality of studies
This meta-analysis was conducted in accordance with PRISMA guidelines 8 . The quality of the studies was measured using the Newcastle-Ottawa scale, which assesses the methodological quality of non-randomized cohort studies for meta-analysis 9 . The studies were judged by two independent assessors using a nine-point scale comprising analysis based on selection of the study group, the comparability of cohorts and the ascertainment of outcome. Scores above 6 points were taken to denote studies of high methodological quality, and were included in the meta-analysis.
Meta-analysis of CIMP status, clinicopathological factors and survival
Methylation of the promoter region of a gene results in epigenetic silencing and a subsequent loss of expression of the target protein. There are two possible explanations for potentially conflicting survival results; first, the observed prognostic association between CIMP status and survival is influenced by the choice of gene panel; second, the clinicopathological make-up of the cohort identifies different molecular subtypes of CIMP tumours. To test the first hypothesis, studies and genes were grouped by survival and oncogenes/TSGs. To test the second hypothesis, comparisons were made between clinicopathological factors and the CIMP status of the meta-cohorts, when studies were dichotomized based on the reported survival observed.
Statistical analysis
All analyses were conducted with the RevMan statistical package (Review Manager version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Heterogeneity between studies was tested using Cochran's G test. The I 2 statistic was calculated for an objective measure of heterogeneity. A fixed-effect meta-analysis was performed in all analyses, and where there was appreciable heterogeneity (I 2 over 50 per cent or P < 0⋅100 in χ 2 test), a random-effects model was used. Corresponding funnel plots of Ln standard error as a function of effect size were used to examine the effect of publication bias visually, and were tested statistically using Egger's test. P > 0⋅050 was indicative of absence of publication bias. For meta-analysis, Mantel-Haenszel ORs for CIMP status and 5-year death rate were calculated with 95 per cent confidence intervals. Sensitivity analysis was performed to identify whether any methodological features were indicative of heterogeneity among studies. Studies were excluded if they were of poor methodological quality (Newcastle-Ottawa scale score below 7). An et al. 13 Ben Ayed-Guerfali et al. 14 Chen et al. 15 Chang et al. 16 He et al. 4 Ksiaa et al. 17 Kusano et al. 11 Liu 10 Park et al. 3 Shigeyasu et al. 12 Total Heterogeneity: χ 2 = 75·60, 9 d.f., P < 0·001; I 2 = 88% Test for overall effect: Z = 2·61, P = 0·009 
Results
The electronic search of the literature yielded 110 potential studies. A grey search through cross-referencing did not yield any additional articles. Of the 110 studies, 96 were excluded based on the contents of the abstract (Fig. 1) . Forty-four studies concerned non-gastric cancers, four looked at single gene methylations, and 48 did not include survival information. Of the 14 studies undergoing full-text evaluation, four did not include survival information and so ten studies were retained for final analysis 3,4,10 -17 . Baseline characteristics are summarized in Table 1 . The median quality score for the studies was 9 (range 8-9). All were retrospective cohort studies of one or regional institutions. All studies reporting methylation of CpG islands on promoter regions of genes were based on resected specimens. The ten studies contained 918 patients with a median sample size of 81 (range 68-147). Only three studies contained more than 100 patients. Eight studies included patients with TNM stage I-IV disease; only Ben Ayed-Guerfali et al. 14 and Liu 10 included patients with stage I-III disease. The approximate median age of the patients was 60 years, and most were men (range 59-82 per cent). Nine studies gave no information on the use of chemotherapy; only An and co-workers 13 reported that neoadjuvant chemotherapy was not prescribed.
CpG island methylation was quantified on a median of 5⋅5 (range 5-28) genes. The range of genes used is shown in Table 2 . The CIMP categorization thresholds varied, however, and the most common groupings were a trichotomy of CIMP-N, CIMP-L and CIMP-H. The prevalence of CIMP-H ranged from 4⋅8 to 63 per cent, with a median of 40⋅9 per cent. Five studies 11 -13,16,17 reported an association between CIMP-H and improved survival, four 3, 4, 14, 15 reported an association with poorer survival, and a single study 10 reported no statistically significant association with survival ( Table 2) .
Meta-analysis of CIMP status, clinicopathological factors and survival
For the purposes of pooled analysis, CIMP-H (CIMP-positive) was compared with a combined grouping of CIMP-L and CIMP-N (CIMP-negative). The pooled OR for death in the CIMP-positive versus CIMP-negative group was 1⋅48 (95 per cent c.i. 1⋅10 to 1⋅99). Significant study heterogeneity was noted (χ 2 = 75⋅60, 9 d.f., P < 0⋅001, I 2 = 88 per cent (Fig. 2) .
Studies and genes were grouped in relation to survival and oncogene/TSGs respectively ( Table S1 , supporting information). Studies demonstrating an association between CIMP positivity and improved survival had gene panels consisting of TSGs and oncogenes. In the studies demonstrating an association between CIMP positivity and poor outcome, apart from that of Park and colleagues 3 , all had gene panels that included TSGs predominantly.
Comparisons were made between clinicopathological factors and the CIMP status of the meta-cohorts when studies were dichotomized based on the reported survival. The only extractable data related to clinicopathological factors were sex and TNM stage; the latter was classified The frequency of men in studies reporting improved survival was 66⋅7 per cent, compared with 69⋅6 per cent in studies reporting poor survival (P = 0⋅440). The proportion of patients with advanced disease in studies reporting improved survival was 53⋅5 per cent, compared with 68⋅0 per cent in the studies reporting poor survival (P < 0⋅001). The ratio of CIMP negativity to positivity was 2⋅3 in the cohort with poor survival, and 2⋅1 in that with improved survival. Despite this, CIMP positivity was associated with advanced TNM stage in the cohort with poor survival (P < 0⋅001) ( Table S2 , supporting information). The association between CIMP positivity and early stage in the cohort with improved survival was not statistically significant (P = 0⋅061).
Subgroup pooled analysis of death rates according to whether studies showed a tendency towards poor (5 studies) or improved (5) outcomes, revealed that CIMP-H was associated with both poor (OR 8⋅15, 4⋅65 to 14⋅28, P < 0⋅001; heterogeneity I 2 = 52 per cent, P = 0⋅08) and improved survival (OR 0⋅42, 0⋅27 to 0⋅65; P < 0⋅001, heterogeneity I 2 = 0 per cent, P = 0⋅960).
Discussion
This study found marked variability in the genes employed in the selection panel for determining CIMP status, with clear heterogeneity related to survival. Five studies showed associations with improved survival, and four demonstrated associations with poor survival. The 5-year survival rate for the CIMP-positive group ranged from 73⋅7 per cent in studies reporting improved survival to 14⋅3 per cent in those reporting poor survival. The reasons for these observations were unclear, but likely reflect the make-up of the individual patient cohorts and gene selection panel, as the meta-cohort with poor survival had a higher proportion of advanced disease, and the gene panel was predominantly composed of TSGs. The lack of a consensus regarding CIMP status methodology in gastric cancer makes it challenging to translate this potential biomarker into clinical practice.
Heterogeneity in the methodology for determining CIMP status was a major finding, with the number, type and identity of genes employed in the selection panel different in every study. Such findings have also been noted in colorectal cancer; Jia and colleagues 20 reported that in 16 studies the number of markers ranged from five to 15, and different critical values were used. The prevalence of CIMP ranged from 6⋅4 to 48⋅5 per cent in colorectal cancer, compared with 5⋅3 to 94⋅1 per cent in gastric cancer. It is possible that methylation occurs in a number of CpG islands, which has little influence on the phenotype of the cancer, but it is not known to what extent these methylated genes are passengers, rather than drivers. Having the CIMP panel composed of cancer drivers may provide a better picture of the pathogenesis and prognostic impact of CIMP.
Meta-analysis of cohorts in which CIMP was associated with poor outcomes revealed that CIMP was associated with a more advanced TNM stage, yet in a meta-analysis of cohorts in which CIMP improved outcomes CIMP positivity was associated with earlier TNM stage. The reason for this is unclear, but the finding emphasizes the importance of using study cohorts that reflect the population being treated. Standardized biomarker reporting, including the cohort composition, adds to result reliability, which is particularly important given the variability in stage and survival observed between Eastern and Western populations. It is possible that cancers arising from these cohorts are phenotypically different, but this can only be evaluated once the optimum methodology has been agreed and validated.
The ten studies in this systematic review used 59 different genes. This was not a comprehensive analysis of cancer-related genes, with less than 1 per cent of the genome studied. It is now becoming clearer that cancer-related genes may be described as drivers or passengers depending on their influence on carcinogenesis, growth and metastasis. It possible that tumours with large numbers of methylated passenger genes are identified as CIMP despite such genes having little influence on the final phenotype and subsequent prognosis. Epigenetic silencing of the hMLH1 gene, which leads to loss of mismatch repair protein expression and the microsatellite instability (MSI) phenotype, has been associated with improved survival in both colorectal and gastric cancer 2, 20 . Furthermore, in the present systematic review, studies using hMLH1 in the gene panel were all associated with improved survival. In colorectal cancer, the CIMP+/MSI+ phenotype is a recognized entity associated with improved survival. hMLH1 can be identified confidently as a cancer driver and therefore the CIMP+/hMLH1 subtype likely explains the observed improved survival in some of the CIMP studies. However, it remains unclear why CIMP was associated with poor survival in a subset of studies; this deserves further evaluation.
The Cancer Genome Atlas Research Network 21 identified four molecularly distinct subtypes of gastric cancer, based on Epstein-Barr virus (EBV), MSI, chromosomal instability and genomic stability. In particular, EBV and MSI gastric cancer were reported to be associated with hypermethylation of promoter regions of up to 526 genes. Based on molecular associations, four cluster patterns of hypermethylation have been reported, with two attributed to EBV and MSI gastric cancer; unfortunately, neither survival analysis nor a defined classification for CIMP was given. Nevertheless, it is clear that there is heterogeneity, even within a hypermethylation subgroup, which is likely to lead to different associations with survival. Therefore, the different gene panels employed in this systematic review may identify subtypes of CIMP, and consensus regarding methodology is desirable.
The value of CIMP as a predictive biomarker to guide whether or not to prescribe neoadjuvant or adjuvant chemotherapy is uncertain. Shiovitz and co-workers 22 reported that, in patients with stage III colorectal cancer undergoing fluorouracil/leucovorin therapy, CIMP positivity was associated with poorer survival compared with CIMP negativity, consistent with chemotherapy resistance. The proportion of patients with gastric cancer responding to neoadjuvant chemotherapy has been reported to be around 21 per cent; although performing CIMP analysis on diagnostic biopsies is possible 23 , this strategy might not be pragmatic because of the variable amount of cancer genomic material available within any biopsy, and such an approach would require validation. Nevertheless, CIMP is a promising biomarker for the management of patients with gastric cancer. Further work to quantify and validate this technique to determine its relationship with responses to contemporary chemotherapeutic algorithms may support its integration into clinical practice.
This study has a number of inherent limitations, in the main related to the spectrum of gene panel markers used for CIMP. Unfortunately, this is a common finding pervading CIMP studies, and other systematic reviews and meta-analyses in colorectal cancer 20 and gastric cancer 5 have accepted this relative limitation when performing pooled analyses. In contrast, the study has significant strength in that it is a systematic review and meta-analysis of prognostic studies relating to CIMP in gastric cancer, and the studies included were methodologically sound with Newcastle-Ottawa scales scores exceeding 7.
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